Logo image
Back
Effects of Colchicine on IgE-Mediated Early and Late Airway Reactions
Journal article   Peer reviewed

Effects of Colchicine on IgE-Mediated Early and Late Airway Reactions

Stephen J Kelly, Andrew J Uri, Howard S Freeland, Essie J Woods, Edward S Schulman, Stephen P Peters and James E Fish
Chest, v 107(4), pp 985-991
Apr 1995
DOI: https://doi.org/10.1378/chest.107.4.985
PMID: 7535676
Featured in Collection :   UN Sustainable Development Goals @ Drexel

Abstract

colchicine methacholine responsiveness acute airway reaction early and late phase allergen responses Asthma
The pathogenesis of bronchial asthma is thought to involve elements of both acute and chronic inflammation. Hence, there is growing interest in the potential of immunomodulatory drugs in asthma therapy. This study examines the effects of the anti-inflammatory compound colchicine on early and late allergen-induced, IgE-mediated airway reactions. Nine mildly allergic asthmatic subjects were evaluated in a single-blind, two-way crossover study designed to examine the effects of colchicine and placebo on early and late airway reactions to ragweed allergen and related changes in nonspecific responsiveness to methacholine. Compared with placebo, colchicine provided 19% (p=0.036) and 40% (p=0.004) inhibition of early and late airway reactions to allergen, respectively. Allergen-induced increases in methacholine responsiveness were observed with both types of treatment, although there was a trend toward a smaller increase after administration of colchicine (p=0.13). We also found that methacholine responsiveness per se was not directly altered by colchicine (n=7). In 6 subjects, we found suppression of neutrophil leukotriene B4 generation after colchicine treatment, suggesting that the colchicine dose (0.6 mg twice daily) was sufficient to produce an anti-inflammatory effect. Further in vitro studies using purified human lung tissue mast cells failed to demonstrate inhibition of mediator release at concentrations corresponding to achievable tissue or blood levels during the in vivo trial. Colchicine partially inhibits IgE-mediated early and late airway reactions at conventional clinical doses. This inhibitory effect may be mediated via suppression of some cell species other than the lung tissue mast cell. Controlled studies to examine the benefits of colchicine in clinically evidenced asthma are warranted.

Metrics

16 Record Views
21 citations in Web of Science
27 citations in Scopus

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Collaboration types
Domestic collaboration
Web of Science research areas
Critical Care Medicine
Respiratory System
Logo image